Research AboutOfferDocumentationLoginBook a demo
ResearchAboutOfferLoginBook a demo

Hepagene Therapeutics

Ownership
Private
Therapeutic Areas
GastroenterologyMetabolic DisordersEndocrinologyOncologyInfectious Diseases
Stage
Phase 2
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small molecule drugsiRNA

Hepagene Therapeutics General Information

Hepagene Therapeutics is a clinical stage drug discovery and development company focused on liver diseases. The company has multiple programs in development, with its lead candidates HPG-1860 (FXR agonist) in Phase 1 for Sclerosing Cholangitis and HPG-7233 (THR-β agonist) in IND Application stage for NASH.

Contact Information

Website
https://www.hepagene.com/
Primary Industry
Biotech
Corporate Office
Shanghai, Shanghai Shi
China

Drug Pipeline

HPG1860
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Hepagene Therapeutics's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Hepagene Therapeutics Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Hepagene Therapeutics's complete valuation and funding history, request access »

Hepagene Therapeutics Financial Metrics

See full profile
Book a demo
OverviewDrug PipelineTechnologiesPartnershipsFundingCompetitorsAnalysisPatentsLicensing Deals